Home Cart Sign in  
Chemical Structure| 1009119-65-6 Chemical Structure| 1009119-65-6

Structure of Daclatasvir 2HCl
CAS No.: 1009119-65-6

Chemical Structure| 1009119-65-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent, orally active HCV NS5A protein inhibitor with EC50s ranging from 9 to 146 pM for multiple HCV replicon genotypes. It also inhibits organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 with IC50s of 1.5 µM and 3.27 µM, respectively.

Synonyms: BMS-790052 dihydrochloride; EBP 883 dihydrochloride; Daclatasvir dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Daclatasvir 2HCl

CAS No. :1009119-65-6
Formula : C40H52Cl2N8O6
M.W : 811.80
SMILES Code : O=C([C@@H](NC(OC)=O)C(C)C)N1[C@@H](CCC1)C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O.Cl.Cl
Synonyms :
BMS-790052 dihydrochloride; EBP 883 dihydrochloride; Daclatasvir dihydrochloride
MDL No. :MFCD25541736
InChI Key :BVZLLUDATICXCI-JMSCDMLISA-N
Pubchem ID :25154713

Safety of Daclatasvir 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7.5.1 cells 10 μM 2 hours To evaluate the inhibitory effect of Daclatasvir on HCV infection PMC7677215
Huh7.5.1 cells 10 μM 48 hours To evaluate the inhibitory effect of Daclatasvir on HCV infection, results showed significant reduction in viral RNA levels. PMC6420960
RDEB fibroblasts 1 µM 48 hours To investigate the effect of Daclatasvir on the TGF-β signaling pathway, results showed that Daclatasvir inhibited the expression of TGF-β pathway targets collagen I, phosphorylated AKT, and phosphorylated SMAD3. PMC11018630

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
humanized chimeric mice HCV genotype 1b, 2a or 3 infection model oral 1 and 2 mg/kg/day once daily for 2.5 months (P301S Tau mice) or 9 months (3xTg mice) To evaluate the efficacy of Daclatasvir monotherapy on HCV infection, results showed a decline in viral load but with emerging resistance PMC7677215
mice Alb-uPA/SCID chimeric mice intraperitoneal injection 100 mg/kg Single injection, samples taken after 48 hours To evaluate the inhibitory effect of Daclatasvir on HCV infection in vivo, results showed significant reduction in viral titers. PMC6420960
Mice MC38 tumor model Intraperitoneal injection 10 mg/kg daily for 4 weeks Daclatasvir significantly suppressed the growth of MC38 tumors and activated CD44+CD8+ T cells in the tumor microenvironment. PMC11227557
Mice RDEB mouse model Drinking water 50 mg/kg once daily for 4 weeks To evaluate the preventive effect of Daclatasvir on fibrosis in RDEB mice, results showed that Daclatasvir significantly improved survival, weight gain, activity, and reduced the development of fibrosis. PMC11018630
Mice Alb-uPA/SCID mouse model Intraperitoneal injection 3×10^5 cells Single injection, lasting 4 weeks To evaluate the in vivo inhibitory effect of Boceprevir on HCV genotype 1b and 2a, results showed that Boceprevir significantly reduced viral titers without evidence of drug resistance during the treatment period. PMC6420960

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03748745 Drug Interactions Phase 1 Active, not recruiting January 19, 2019 China, Jilin ... More >> Phase I Clinical Trial Unit, The First Hospital of Jilin University Changchun, Jilin, China, 130000 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.23mL

0.25mL

0.12mL

6.16mL

1.23mL

0.62mL

12.32mL

2.46mL

1.23mL

References

 

Historical Records

Categories